Bluebird Bio Current Valuation vs. Revenue

BLUE Stock  USD 0.38  0.01  2.56%   
Considering Bluebird Bio's profitability and operating efficiency indicators, Bluebird bio may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Bluebird Bio's ability to earn profits and add value for shareholders. The current year's Sales General And Administrative To Revenue is expected to grow to 6.41, whereas Price To Sales Ratio is forecasted to decline to 4.88. At present, Bluebird Bio's Income Tax Expense is projected to increase significantly based on the last few years of reporting. The current year's Non Operating Income Net Other is expected to grow to about 33.4 M, whereas Operating Income is forecasted to decline to (256.5 M).
For Bluebird Bio profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bluebird Bio to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bluebird bio utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bluebird Bio's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bluebird bio over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bluebird Bio. If investors know Bluebird will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bluebird Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(34.93)
Revenue Per Share
0.357
Quarterly Revenue Growth
1.337
Return On Assets
(0.36)
Return On Equity
(1.87)
The market value of Bluebird bio is measured differently than its book value, which is the value of Bluebird that is recorded on the company's balance sheet. Investors also form their own opinion of Bluebird Bio's value that differs from its market value or its book value, called intrinsic value, which is Bluebird Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bluebird Bio's market value can be influenced by many factors that don't directly affect Bluebird Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bluebird Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bluebird Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bluebird Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Bluebird bio Revenue vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Bluebird Bio's current stock value. Our valuation model uses many indicators to compare Bluebird Bio value to that of its competitors to determine the firm's financial worth.
Bluebird bio is rated below average in current valuation category among its peers. It is rated below average in revenue category among its peers totaling about  0.08  of Revenue per Current Valuation. The ratio of Current Valuation to Revenue for Bluebird bio is roughly  12.68 . At present, Bluebird Bio's Total Revenue is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Bluebird Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Bluebird Current Valuation vs. Competition

Bluebird bio is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 42.42 Billion. Bluebird Bio maintains roughly 373.9 Million in current valuation contributing less than 1% to equities under Health Care industry.

Bluebird Revenue vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Bluebird Bio

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
373.9 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Bluebird Bio

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
29.5 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Bluebird Revenue vs Competition

Bluebird bio is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 3.28 Billion. Bluebird Bio maintains roughly 29.5 Million in revenue contributing less than 1% to equities under Health Care industry.

Bluebird Bio Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Bluebird Bio, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Bluebird Bio will eventually generate negative long term returns. The profitability progress is the general direction of Bluebird Bio's change in net profit over the period of time. It can combine multiple indicators of Bluebird Bio, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-3.7 M-3.8 M
Operating Income-244.3 M-256.5 M
Income Before Tax-212 M-222.6 M
Total Other Income Expense Net38.7 M40.6 M
Net Loss-211.9 M-222.5 M
Income Tax Expense134.6 K141.3 K
Net Loss-211.9 M-222.5 M
Non Operating Income Net Other31.8 M33.4 M
Net Loss-239.9 M-251.9 M
Interest Income9.9 M7.6 M
Net Interest Income-6.5 M-6.2 M
Change To Netincome-60.1 M-57.1 M
Net Loss(1.93)(2.03)
Income Quality 1.11  1.16 
Net Income Per E B T 1.00  0.78 

Bluebird Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Bluebird Bio. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bluebird Bio position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bluebird Bio's important profitability drivers and their relationship over time.

Use Bluebird Bio in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bluebird Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bluebird Bio will appreciate offsetting losses from the drop in the long position's value.

Bluebird Bio Pair Trading

Bluebird bio Pair Trading Analysis

The ability to find closely correlated positions to Bluebird Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bluebird Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bluebird Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bluebird bio to buy it.
The correlation of Bluebird Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bluebird Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bluebird bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bluebird Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Bluebird Bio position

In addition to having Bluebird Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Consumer Funds Thematic Idea Now

Consumer Funds
Consumer Funds Theme
Funds or Etfs that invest in consumer products such as packaged goods, clothing, food, beverages and retail services. The Consumer Funds theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Bluebird bio is a strong investment it is important to analyze Bluebird Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bluebird Bio's future performance. For an informed investment choice regarding Bluebird Stock, refer to the following important reports:
Check out Trending Equities.
For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
To fully project Bluebird Bio's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Bluebird bio at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Bluebird Bio's income statement, its balance sheet, and the statement of cash flows.
Potential Bluebird Bio investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Bluebird Bio investors may work on each financial statement separately, they are all related. The changes in Bluebird Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bluebird Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.